HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: an update.

Abstract
Since the last review in 2007 of thrombotic thrombocytopenic purpura (TTP) and microangiopathic hemolytic anemia in the Clinics, further understanding of the nature of TTP and atypical hemolytic uremic syndrome (aHUS) has led to increasing use of rituximab in the treatment of TTP and the approval in 2011 of eculizumab for the treatment of aHUS. With this new armamentarium, distinction of aHUS from TTP has become more critical than ever. This article updates the new knowledge, highlights the difference between aHUS and TTP, and presents a scheme for their diagnosis and management.
AuthorsHan-Mou Tsai
JournalHematology/oncology clinics of North America (Hematol Oncol Clin North Am) Vol. 27 Issue 3 Pg. 565-84 (Jun 2013) ISSN: 1558-1977 [Electronic] United States
PMID23714312 (Publication Type: Case Reports, Journal Article, Review)
CopyrightCopyright © 2013 Elsevier Inc. All rights reserved.
Chemical References
  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human
Topics
  • ADAM Proteins
  • ADAMTS13 Protein
  • Adult
  • Animals
  • Atypical Hemolytic Uremic Syndrome
  • Diagnosis, Differential
  • Female
  • Hemolytic-Uremic Syndrome (diagnosis, etiology, therapy)
  • Humans
  • Male
  • Middle Aged
  • Purpura, Thrombotic Thrombocytopenic (diagnosis, etiology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: